Department of Medicine, Hematology and Oncology, Ruhr-University of Bochum, Knappschaftskrankenhaus Bochum-Langendreer, In der Schornau 23/25, 44892, Bochum, Germany.
J Neurooncol. 2012 Sep;109(2):239-44. doi: 10.1007/s11060-012-0908-2. Epub 2012 Jun 23.
Diagnosis of primary lymphomas of the central nervous system (PCNSL) largely depends on histopathology of tumor biopsies. Recently, we identified miRNAs detected in the CSF of PCNSL patients as novel non-invasive biomarkers for this disease. In combined analyses of miR-21, miR-19b, and miR-92 CSF levels, it was possible to differentiate PCNSL from other neurological disorders. In the current study, we first confirmed our previous findings in an enlarged PCNSL cohort (n = 39; sensitivity 97.4 %). Also, we sought to establish the potential role of CSF miRNAs as biomarkers for disease course monitoring. In sequential miRNA measurements in CSF derived from nine patients with different disease courses, an intriguing correlation of miRNA levels and PCNSL status during treatment and/or disease follow-up was demonstrated. Finally, we demonstrated that miRNA levels in serum of PCNSL patients (n = 14) were not elevated as compared to controls. In summary, this study provides the first evidence that CSF miRNAs have the potential as biomarkers for treatment monitoring and disease follow-up of patients with PCNSL.
原发性中枢神经系统淋巴瘤（PCNSL）的诊断在很大程度上依赖于肿瘤活检的组织病理学。最近，我们发现 PCNSL 患者脑脊液中存在的 microRNA 可作为该疾病的新型非侵入性生物标志物。在对 miR-21、miR-19b 和 miR-92 的脑脊液水平进行联合分析时，能够将 PCNSL 与其他神经疾病区分开来。在本研究中，我们首先在一个扩大的 PCNSL 队列中验证了我们之前的发现（n = 39；敏感性 97.4%）。此外，我们试图确定 CSF microRNA 作为疾病过程监测的生物标志物的潜在作用。在 9 名不同疾病过程患者的脑脊液中进行的连续 miRNA 测量中，miRNA 水平与治疗期间和/或疾病随访期间 PCNSL 状态之间存在有趣的相关性。最后，我们证明了 PCNSL 患者（n = 14）血清中的 miRNA 水平与对照组相比并未升高。综上所述，本研究首次证明了 CSF microRNA 具有作为 PCNSL 患者治疗监测和疾病随访的生物标志物的潜力。
